Larotinib/Larotinib Common Side Effects and Guidelines for Countermeasures

Larotrectinib is an oral targeted drug targeting NTRK gene fusion. It is suitable for solid tumors of various tissue origins. It can benefit as long as NTRK fusion exists. It is classified as a "tissue-independent" anti-tumor drug. Although the drug has good target selectivity and tolerability, it still has certain side effects during use, which requires the joint attention and management of patients and medical staff.

The most common side effects include fatigue, dizziness, constipation, nausea, and abnormal liver function. Most of these adverse reactions are mild to moderate and can be alleviated through symptomatic treatment. Fatigue may be related to changes in energy metabolism in the body. It is recommended that patients maintain a regular schedule, avoid strenuous activities, and supplement nutrition appropriately to help improve their energy status. Dizziness often occurs in the early stages of medication. You should avoid driving or performing high-risk operations, and monitor changes in blood pressure to rule out hypotension caused by the medication.

In terms of gastrointestinal symptoms, constipation and nausea are more common. Strategies to cope with constipation include increasing water intake, dietary fiber intake, moderate exercise, and the use of mild laxatives when necessary. Nausea symptoms can be alleviated by adjusting the diet before and after taking the drug, or by using antiemetic drugs in combination. Some patients may experience elevated transaminases, and liver function needs to be monitored regularly. If the increase is significant, the dose may be adjusted or the medication may be suspended according to medical advice.

It is worth noting that a very small number of patients may experience neurological side effects, such as coordination disorders or slow reactions, which prompts the need to closely observe changes in neurological status, especially in the elderly and those with other underlying diseases. If you notice any abnormal behavior after taking medication, you should seek medical evaluation immediately.

In short, most of the adverse reactions of larotrectinib are controllable and reversible, and the smooth progress of treatment can be ensured with the help of drug monitoring and reasonable management. During the medication period, patients should regularly review liver function, electrolytes, blood routine and other indicators, truthfully report any discomfort and reactions, and cooperate with the doctor to adjust the treatment plan to achieve the goal of long-term safe medication.

Reference materials:https://www.vitrakvi.com/